386 related articles for article (PubMed ID: 37958890)
1. Targeting the DNA Damage Response for Cancer Therapy.
Wang R; Sun Y; Li C; Xue Y; Ba X
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958890
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
3. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
4. PARP1: Structural insights and pharmacological targets for inhibition.
Spiegel JO; Van Houten B; Durrant JD
DNA Repair (Amst); 2021 Jul; 103():103125. PubMed ID: 33940558
[TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: Past, present, and future.
Hu ML; Pan YR; Yong YY; Liu Y; Yu L; Qin DL; Qiao G; Law BY; Wu JM; Zhou XG; Wu AG
Ageing Res Rev; 2023 Nov; 91():102078. PubMed ID: 37758006
[TBL] [Abstract][Full Text] [Related]
6. PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance.
Kanev PB; Atemin A; Stoynov S; Aleksandrov R
Semin Oncol; 2024; 51(1-2):2-18. PubMed ID: 37714792
[TBL] [Abstract][Full Text] [Related]
7. [PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective].
Wiśnik E; Ryksa M; Koter-Michalak M
Postepy Hig Med Dosw (Online); 2016 Apr; 70():280-94. PubMed ID: 27117104
[TBL] [Abstract][Full Text] [Related]
8. PARP mediated DNA damage response, genomic stability and immune responses.
Zong C; Zhu T; He J; Huang R; Jia R; Shen J
Int J Cancer; 2022 Jun; 150(11):1745-1759. PubMed ID: 34952967
[TBL] [Abstract][Full Text] [Related]
9. Mitotic functions of poly(ADP-ribose) polymerases.
Slade D
Biochem Pharmacol; 2019 Sep; 167():33-43. PubMed ID: 30910692
[TBL] [Abstract][Full Text] [Related]
10. Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy.
Peng X; Pan W; Jiang F; Chen W; Qi Z; Peng W; Chen J
Pharmacol Res; 2022 Dec; 186():106529. PubMed ID: 36328301
[TBL] [Abstract][Full Text] [Related]
11. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic insight into the role of Poly(ADP-ribosyl)ation in DNA topology modulation and response to DNA damage.
Matkarimov BT; Zharkov DO; Saparbaev MK
Mutagenesis; 2020 Feb; 35(1):107-118. PubMed ID: 31782485
[TBL] [Abstract][Full Text] [Related]
13. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
Zhang L; Li DQ
Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
15. The regulation loop of MARVELD1 interacting with PARP1 in DNA damage response maintains genome stability and promotes therapy resistance of cancer cells.
Sun H; Liu C; Han F; Lin X; Cao L; Liu C; Ji Q; Cui J; Yao Y; Wang B; Liao Y; Nie H; Zhang Y; Li Y
Cell Death Differ; 2023 Apr; 30(4):922-937. PubMed ID: 36750717
[TBL] [Abstract][Full Text] [Related]
16. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
17. A PARP1-TIMELESS alliance in cancer therapy.
Tarsounas M
Mol Cell; 2024 May; 84(10):1824-1825. PubMed ID: 38759623
[TBL] [Abstract][Full Text] [Related]
18. The role of PARP1 in the DNA damage response and its application in tumor therapy.
Wang Z; Wang F; Tang T; Guo C
Front Med; 2012 Jun; 6(2):156-64. PubMed ID: 22660976
[TBL] [Abstract][Full Text] [Related]
19. Nuclear DJ-1 Regulates DNA Damage Repair via the Regulation of PARP1 Activity.
Wang ZX; Liu Y; Li YL; Wei Q; Lin RR; Kang R; Ruan Y; Lin ZH; Xue NJ; Zhang BR; Pu JL
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239999
[TBL] [Abstract][Full Text] [Related]
20. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo.
Shao Z; Lee BJ; Rouleau-Turcotte É; Langelier MF; Lin X; Estes VM; Pascal JM; Zha S
Nucleic Acids Res; 2020 Sep; 48(17):9694-9709. PubMed ID: 32890402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
